Jeroen Kortekaas

Jeroen Kortekaas is the head of the Bunyavirus Research Group of Wageningen Bioveterinary Research (WBVR), Professor of Veterinary Arbovirology of Wageningen University and CSO of BunyaVax. He is also member of the board of the Virology Division of the Royal Netherlands Academy of Arts and Sciences and member of the Netherlands Commission on Genetic Modification (COGEM). In the past 12 years, his research has focused on Rift Valley fever virus (RVFV) vaccine development. He is taking part in the Zoonoses Anticipation and Preparedness Initiative (ZAPI: http://www.zapi-imi.eu/), a public-private project that aims to develop novel pipelines for the development of vaccines and antibodies against emerging zoonotic diseases, using RVFV as a model pathogen. In 2017, he co-founded BunyaVax (www.bunyavax.com) , a company that develops vaccines using proprietary bunyavirus-based vaccine technologies. In the same year, he was appointed Special Professor of Veterinary Arbovirology, affiliated with the Laboratory of Virology of Wageningen University. He is coordinator of the “Long-term Europe-Africa Research Network” (LEARN: www.learn-project.nl) on arboviral zoonoses, a research consortium aimed to improve EU-Africa collaborations on arbovirus research. In 2019, he became coordinator of the LARISSA project (www.larissa-online), funded by the Coalition for Epidemic Preparedness Innovations (CEPI) in which a human RVF vaccine is being developed.